Jaspal Patil

Jaspal Patil

Auto-generated profile, based on publicly available information

Jaspal Patil

Innoplexus Consulting Services Pvt Ltd, Pune, Maharashtra, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Neuropharmacology
Verified
Journal Article
Closed access
MSMats Sandberg
Mats Sandberg
JPJaspal Patil
Jaspal Patil
BDBarbara D'Angelo
Barbara D'Angelo
SWStephen G. Weber
Stephen G. Weber
CMCarina Mallard
Carina Mallard

9 May 2024 in The Protein Journal
Verified
Journal Article
Closed access
PDF file
AGAkshata Gavade
Akshata Gavade
ANAnil Kumar Nagraj
Anil Kumar Nagraj
RPRiya Patel
Riya Patel
RPRoylan Pais
Roylan Pais
PDPratiksha Dhanure
Pratiksha Dhanure
JPJaspal Patil
Jaspal Patil

23 January 2025 in Human Antibodies
Verified
Journal Article
Closed access
RPRoylan Pais
Roylan Pais
ANAnil Kumar Nagraj
Anil Kumar Nagraj
AGAkshata Gavade
Akshata Gavade
RPRiya Patel
Riya Patel
MMMohasin Momin
Mohasin Momin
JPJaspal Patil
Jaspal Patil
Background: Antibodies are composed of light and heavy chains, both of which have constant and variable regions. The diversity, specific binding ability and therapeutic potential of antibodies are determined by hypervariable loops called complementarity-determining regions (CDRs), with the other regions being the framework regions. Objective: To investigate the key amino acid patterns in various antibody regions in the human therapeutic antigen-antibody (Ag-Ab) complexes collected from the Thera-SAbDab database. Method: The study focuses on identifying the amino acid frequency, diversity index in CDRs, paratope-epitope amino acid interactions, amino acid bond formation frequency, and bond types among selected therapeutic Ag-Ab complexes. Results: The results revealed that Ser is highly distributed in the overall light chain CDRs while Gly is highly distributed in the heavy chain CDRs. CDR profiling analysis indicated that the average amino acid diversity in heavy chain CDRs is 60% to 70%, while in the light chain, it is 50% to 60%. Aromatic residues such as Tyr, Trp and Phe are the top contributors to these paratope-epitope interactions in the light and heavy chains. Moreover, we examined the frequency of amino acids in light and heavy chains of Ag-Ab complexes. Importantly, the outcome of this study leverages the in depth analysis on single residues, dipeptides, and tripeptides for the therapeutic Ag-Ab complexes. Conclusion: We conclude that the amino acid frequency and interaction analysis centered on therapeutic Ag-Ab complexes will benefit antibody engineering parameters such as antibody design, optimization, affinity maturation, and overall antibody development.

8 January 2025 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
RPRoylan Pais
Roylan Pais
ANAnil Kumar Nagraj
Anil Kumar Nagraj
RPRiya Patel
Riya Patel
AGAkshata Gavade
Akshata Gavade
MMMohasin Momin
Mohasin Momin
JPJaspal Patil
Jaspal Patil